These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 38972295)
1. Redox-dependent plasticity of oxMIF facilitates its interaction with CD74 and therapeutic antibodies. Sajko S; Skeens E; Schinagl A; Ferhat M; Mirkina I; Mayer J; Rossmueller G; Thiele M; Lisi GP Redox Biol; 2024 Sep; 75():103264. PubMed ID: 38972295 [TBL] [Abstract][Full Text] [Related]
2. Nanosecond Dynamics Regulate the MIF-Induced Activity of CD74. Pantouris G; Ho J; Shah D; Syed MA; Leng L; Bhandari V; Bucala R; Batista VS; Loria JP; Lolis EJ Angew Chem Int Ed Engl; 2018 Jun; 57(24):7116-7119. PubMed ID: 29669180 [TBL] [Abstract][Full Text] [Related]
3. Predicted structure of MIF/CD74 and RTL1000/CD74 complexes. Meza-Romero R; Benedek G; Leng L; Bucala R; Vandenbark AA Metab Brain Dis; 2016 Apr; 31(2):249-55. PubMed ID: 26851955 [TBL] [Abstract][Full Text] [Related]
4. Role of the Cysteine 81 Residue of Macrophage Migration Inhibitory Factor as a Molecular Redox Switch. Schinagl A; Kerschbaumer RJ; Sabarth N; Douillard P; Scholz P; Voelkel D; Hollerweger JC; Goettig P; Brandstetter H; Scheiflinger F; Thiele M Biochemistry; 2018 Mar; 57(9):1523-1532. PubMed ID: 29412660 [TBL] [Abstract][Full Text] [Related]
5. A novel allosteric inhibitor of macrophage migration inhibitory factor (MIF). Bai F; Asojo OA; Cirillo P; Ciustea M; Ledizet M; Aristoff PA; Leng L; Koski RA; Powell TJ; Bucala R; Anthony KG J Biol Chem; 2012 Aug; 287(36):30653-63. PubMed ID: 22782901 [TBL] [Abstract][Full Text] [Related]
6. An Analysis of MIF Structural Features that Control Functional Activation of CD74. Pantouris G; Syed MA; Fan C; Rajasekaran D; Cho TY; Rosenberg EM; Bucala R; Bhandari V; Lolis EJ Chem Biol; 2015 Sep; 22(9):1197-205. PubMed ID: 26364929 [TBL] [Abstract][Full Text] [Related]
7. MIF intersubunit disulfide mutant antagonist supports activation of CD74 by endogenous MIF trimer at physiologic concentrations. Fan C; Rajasekaran D; Syed MA; Leng L; Loria JP; Bhandari V; Bucala R; Lolis EJ Proc Natl Acad Sci U S A; 2013 Jul; 110(27):10994-9. PubMed ID: 23776208 [TBL] [Abstract][Full Text] [Related]
8. Migration inhibitory factor enhances inflammation via CD74 in cartilage end plates with Modic type 1 changes on MRI. Xiong C; Huang B; Cun Y; Aghdasi BG; Zhou Y Clin Orthop Relat Res; 2014 Jun; 472(6):1943-54. PubMed ID: 24569872 [TBL] [Abstract][Full Text] [Related]
9. Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory Conditions. Thiele M; Kerschbaumer RJ; Tam FW; Völkel D; Douillard P; Schinagl A; Kühnel H; Smith J; McDaid JP; Bhangal G; Yu MC; Pusey CD; Cook HT; Kovarik J; Magelky E; Bhan A; Rieger M; Mudde GC; Ehrlich H; Jilma B; Tilg H; Moschen A; Terhorst C; Scheiflinger F J Immunol; 2015 Sep; 195(5):2343-52. PubMed ID: 26209628 [TBL] [Abstract][Full Text] [Related]
10. Modeling of both shared and distinct interactions between MIF and its homologue D-DT with their common receptor CD74. Meza-Romero R; Benedek G; Jordan K; Leng L; Pantouris G; Lolis E; Bucala R; Vandenbark AA Cytokine; 2016 Dec; 88():62-70. PubMed ID: 27573366 [TBL] [Abstract][Full Text] [Related]
11. The newly engineered monoclonal antibody ON104, targeting the oxidized Macrophage Migration Inhibitory Factor (oxMIF), ameliorates clinical and histopathological signs of collagen-induced arthritis. Ferhat M; Mangano K; Mirkina I; Mayer J; Rossmueller G; Schinagl A; Kerschbaumer R; Nicoletti F; Thiele M; Landlinger C Eur J Pharmacol; 2023 Oct; 956():175997. PubMed ID: 37579967 [TBL] [Abstract][Full Text] [Related]
12. OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases. Thiele M; Donnelly SC; Mitchell RA J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36180072 [TBL] [Abstract][Full Text] [Related]
13. Targeting of oxidized Macrophage Migration Inhibitory Factor (oxMIF) with antibody ON104 attenuates the severity of glomerulonephritis. Ferhat M; Mayer J; Costa LH; Prendecki M; Tarazona AAP; Schinagl A; Kerschbaumer RJ; Tam FWK; Landlinger C; Thiele M PLoS One; 2024; 19(10):e0311837. PubMed ID: 39374239 [TBL] [Abstract][Full Text] [Related]
15. Macrophage migration inhibitory factor confers resistance to senescence through CD74-dependent AMPK-FOXO3a signaling in mesenchymal stem cells. Xia W; Zhang F; Xie C; Jiang M; Hou M Stem Cell Res Ther; 2015 Apr; 6(1):82. PubMed ID: 25896286 [TBL] [Abstract][Full Text] [Related]
16. A structurally preserved allosteric site in the MIF superfamily affects enzymatic activity and CD74 activation in D-dopachrome tautomerase. Chen E; Reiss K; Shah D; Manjula R; Allen B; Murphy EL; Murphy JW; Batista VS; Bhandari V; Lolis EJ; Lisi GP J Biol Chem; 2021 Sep; 297(3):101061. PubMed ID: 34384784 [TBL] [Abstract][Full Text] [Related]
17. LPS-mediated cell surface expression of CD74 promotes the proliferation of B cells in response to MIF. Klasen C; Ziehm T; Huber M; Asare Y; Kapurniotu A; Shachar I; Bernhagen J; El Bounkari O Cell Signal; 2018 Jun; 46():32-42. PubMed ID: 29476963 [TBL] [Abstract][Full Text] [Related]
18. MIF, CD74 and other partners in kidney disease: tales of a promiscuous couple. Sanchez-Niño MD; Sanz AB; Ruiz-Andres O; Poveda J; Izquierdo MC; Selgas R; Egido J; Ortiz A Cytokine Growth Factor Rev; 2013 Feb; 24(1):23-40. PubMed ID: 22959722 [TBL] [Abstract][Full Text] [Related]
19. CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer. Zheng YX; Yang M; Rong TT; Yuan XL; Ma YH; Wang ZH; Shen LS; Cui L World J Gastroenterol; 2012 May; 18(18):2253-61. PubMed ID: 22611320 [TBL] [Abstract][Full Text] [Related]
20. MIF/CD74 axis participates in inflammatory activation of Schwann cells following sciatic nerve injury. Song H; Zhu Z; Zhou Y; Du N; Song T; Liang H; Chen X; Wang Y; Wang Y; Hu Y J Mol Histol; 2019 Aug; 50(4):355-367. PubMed ID: 31197516 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]